Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
Open Access
- 23 April 2020
- journal article
- research article
- Published by Wiley in Brain Pathology
- Vol. 30 (4) , 831-843
Abstract
Aggregation of the protein α‐synuclein (α‐syn) into insoluble intracellular assemblies termed Lewy bodies (LBs) is thought to be a critical pathogenic event in LB diseases such as Parkinson’s disease and dementia with LBs. In LB diseases, the majority of α‐syn is phosphorylated at serine 129 (pS129), suggesting that this is an important disease‐related post‐translational modification (PTM). However, PTMs do not typically occur in isolation and phosphorylation at the proximal tyrosine 125 (pY125) residue has received considerable attention and has been inconsistently reported to be present in LBs. Furthermore, the proximity of Y125 to S129 means that some pS129 antibodies may have epitopes that include Y125, in which case phosphorylation of Y125 will impede recognition of α‐syn. This would potentially lead to underestimating LB pathology burdens if pY125 occurs alongside pS129. To address the apparent controversy in the literature regarding the detection of pY125, we investigated its presence in the LB pathology. We generated pS129 antibodies whose epitope includes or does not include Y125 and compared the extent of α‐syn pathology recognized in mouse models of α‐synucleinopathies, human brain tissue lysates and fixed post‐mortem brain tissues. Our study demonstrated no difference in α‐syn pathology recognized between pS129 antibodies, irrespective of whether Y125 was part of the epitope or not. Furthermore, evaluation with pY125 antibodies whose epitope does not include S129 demonstrated no labeling of LB pathology. This study reconciles disparate results in the literature and demonstrates pY125 is not a key component of LB pathology in murine models or human tissues in idiopathic LB diseases.Keywords
Funding Information
- Qatar National Research Fund (NPRP8‐517‐3‐112, NPRP9‐213‐1‐043)
This publication has 28 references indexed in Scilit:
- α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?Acta Neuropathologica, 2013
- Elucidating the Role of C-Terminal Post-Translational Modifications Using Protein Semisynthesis Strategies: α-Synuclein Phosphorylation at Tyrosine 125Journal of the American Chemical Society, 2012
- Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formationJournal of Clinical Investigation, 2009
- Tonicity-dependent induction of Sgk1 expression has a potential role in dehydration-induced natriuresis in rodentsJournal of Clinical Investigation, 2009
- Characterization of antibodies that selectively detect α-synuclein in pathological inclusionsActa Neuropathologica, 2008
- α‐Synuclein pathology does not predict extrapyramidal symptoms or dementiaAnnals of Neurology, 2004
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004
- Multiple phosphorylation of α‐synuclein by protein tyrosine kinase Syk prevents eosin‐induced aggregationThe FASEB Journal, 2001
- Activated Fyn Phosphorylates α-Synuclein at Tyrosine Residue 125Biochemical and Biophysical Research Communications, 2001
- α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine KinasesJournal of Biological Chemistry, 2001